Protocol | Link | Focus / Keywords | System | Recent Evidence 2025-26 | Category |
|---|---|---|---|---|---|
echo reporting, minimum dataset, limitations paragraph, study level, loading conditions, image archiving, blinded over-read, quality assurance, medico-legal, incidental findings, handover, PRICES statement | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
ARDS, acute cor pulmonale, RV:LV area ratio 0.6, septal dyskinesia, driving pressure 18, RV-protective ventilation, prone positioning, hypercapnia PVR, inhaled nitric oxide, cardiogenic versus ARDS B-lines | Respiratory | New / Revised 2026 | |||
lung ultrasound, BLUE protocol, A-lines, B-lines, lung sliding, lung point, pneumothorax, consolidation, composite lung-heart table, B-line quantification, diaphragm thickening fraction, DVT compression | Respiratory | New / Revised 2026 | |||
pulmonary embolism, McConnell sign, 60/60 sign, RVOT notching, thrombus in transit, RV:LV ratio, intermediate-high risk, thrombolysis, compression ultrasonography DVT, CTEPH, RV free wall thickness 5 mm | Vascular | New / Revised 2026 | |||
hTEE, continuous miniaturised TEE, indwelling probe, 72 hour dwell, oesophageal pressure injury, serial RV assessment, prone positioning, monitoring versus diagnostic study, no outcome evidence | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
FoCUS, FATE, RUSH, pump tank pipes, FEEL, eFAST, BLUE protocol, staged haemodynamic CCE protocol, checklist, escalation rule, TEE escalation criteria, what each protocol does not answer | Undifferentiated ICU Syndromes | Core Protocol | |||
septic cardiomyopathy, no consensus definition, myocardial depressant factors, mitochondrial dysfunction, beta receptor downregulation, GLS, diastolic dysfunction mortality, reversibility 7-10 days, levosimendan LeoPARDS, esmolol, VA-ECMO | Infectious Diseases | New / Revised 2026 | |||
pregnancy cardiac adaptation, supine hypotension, aortocaval compression, peripartum cardiomyopathy, pre-eclampsia, amniotic fluid embolism, mitral stenosis in pregnancy, maternal cardiac arrest, resuscitative hysterotomy | Obstetrics | New / Revised 2026 | |||
VA-ECMO, VV-ECMO, Impella, IABP, LVAD, cannula position, LV distension, aortic valve opening, Harlequin syndrome, differential hypoxaemia, recirculation, ECMO weaning aortic VTI 10 cm, ramp study, suction event | Cardiovascular | New / Revised 2026 | |||
28-view TEE protocol, mid-oesophageal, transgastric, deep transgastric, bicaval, probe manipulation, anteflex retroflex, SVC collapsibility, ascending aorta blind spot, abbreviated ICU sequence | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
critical care echocardiography textbook, landing page, contents, 43 chapters, ASE 2025 diastolic, ASE 2025 right heart, ASE 2024 prosthetic valves, ESC EACTS 2025 valvular, AHA 2025 CPR, ESICM 2025 haemodynamics | Cardiovascular | Core Protocol | |||
weaning failure, WIPO, weaning-induced pulmonary oedema, spontaneous breathing trial, E/e prime rise, transmural pressure, B-lines, paired study, diaphragm thickening fraction, afterload reduction, prophylactic NIV | Respiratory | New / Revised 2026 | |||
cardiogenic shock, SCAI SHOCK stages, 17-segment model, regional wall motion, RV infarction, ventricular septal rupture, papillary muscle rupture, free wall rupture, pseudoaneurysm, LV thrombus, cardiac power output, PAPi, IABP, Impella | Cardiovascular | New / Revised 2026 | |||
formulas, stroke volume, cardiac output, BSA Du Bois, Bernoulli, PASP, AVA continuity equation, dimensionless index, MVA 220/PHT, PISA EROA, Ea Ees coupling, Devereux LV mass, cardiac power output, worked examples, error propagation | Cardiovascular | Core Protocol | |||
undifferentiated shock, four-question protocol, LVOT VTI, RV:LV ratio, IVC, tamponade, dynamic LVOT obstruction, SAM, vasoplegia, Ea, hyperdynamic ventricle, lung-heart integration, RUSH | Undifferentiated ICU Syndromes | New / Revised 2026 | |||
neurogenic stunned myocardium, subarachnoid haemorrhage, Takotsubo, InterTAK criteria, apical ballooning, dynamic LVOT obstruction, cerebral perfusion pressure, induced hypertension, organ donor assessment, cardioembolic stroke | Neurology | New / Revised 2026 | |||
normal values, reference ranges, severity grading, LVEF, TAPSE, E/e prime, RV grading ASE 2025, valve stenosis thresholds, regurgitation severity, prosthetic valve ASE 2024, patient-prosthesis mismatch, fluid responsiveness thresholds, RAP estimation, Wilkins score | Cardiovascular | Core Protocol | |||
post-cardiotomy tamponade, loculated effusion, clot, paradoxical septal motion, reduced TAPSE after pericardiotomy, SAM after mitral repair, low cardiac output syndrome, baseline prosthetic study, TEE default | Cardiovascular | New / Revised 2026 | |||
abbreviations, glossary, acute cor pulmonale, annulus reversus, Coanda effect, dimensionless index, fluid responsiveness versus tolerance, pseudo-PEA, pressure recovery, RV spiral of death, unmasking, washing jet, WIPO | Miscellaneous / Cross-Cutting | Core Protocol | |||
transesophageal echocardiography, TEE indications, contraindications, oesophageal perforation, probe insertion, jaw thrust, laryngoscope-assisted, high-level disinfection, leak testing, sedation collapse, ETT displacement | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
cardiac arrest, AHA 2025 guidelines, POCUS during CPR, compression interruption, pseudo-PEA, true PEA, cardiac standstill, FEEL, TEE during CPR, post-ROSC, RV dilatation caveat, thrombolysis error | Cardiovascular | New / Revised 2026 | |||
hypertrophic cardiomyopathy, dynamic obstruction, cardiac amyloidosis, apical sparing, 5-5-5 sign, fulminant myocarditis, tachycardia-induced cardiomyopathy, lead-related TR, pacing-induced cardiomyopathy, calcium channel blocker overdose, LAST, lipid emulsion | Cardiovascular | New / Revised 2026 | |||
eFAST, FAST, haemopericardium, pericardial decompression into pleura, blunt cardiac injury, RV contusion, traumatic aortic injury, isthmus, commotio cordis, massive transfusion, citrate hypocalcaemia | Trauma | New / Revised 2026 | |||
mitral regurgitation, Carpentier classification, primary vs secondary MR, atrial functional MR, papillary muscle rupture, flail leaflet, giant v wave, cut-off sign, pulmonary vein systolic reversal, PISA, EROA, SAM | Cardiovascular | New / Revised 2026 | |||
aortic regurgitation, acute severe AR, premature mitral closure, diastolic mitral regurgitation, pressure half time, holodiastolic flow reversal, vena contracta, IABP contraindication, aortic dissection, endocarditis | Cardiovascular | New / Revised 2026 | |||
critical care echocardiography, CCE, basic vs advanced competence, BCCE, ACCE, training standards, credentialling, governance, image archiving, quality assurance, scope of practice, escalation criteria | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
speckle tracking, global longitudinal strain, GLS, RV free wall strain, LA reservoir strain, vendor dependence, 3D echocardiography, 3D LVOT planimetry, ultrasound enhancing agent, artificial intelligence, automated EF | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
LVOT VTI, stroke volume, cardiac output, cardiac index, stroke volume index, low flow state, SVI 35, CSA, Du Bois BSA, SVR, Qp/Qs, thermodilution comparison, serial monitoring | Cardiovascular | New / Revised 2026 | |||
aortic stenosis, AVA, continuity equation, dimensionless index, low-flow low-gradient, paradoxical LFLG, dobutamine stress echo, pseudo-severe, CT calcium score, pressure recovery, energy loss index, TAVI, right parasternal window | Cardiovascular | New / Revised 2026 | |||
TTE views, PLAX, PSAX, apical four chamber, A5C, A2C, subcostal, suprasternal, right parasternal, RV-focused view, staged ICU protocol, foreshortening, end-expiration | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
ejection fraction, EF, Simpson biplane, visual estimation, fractional shortening, EPSS, MAPSE, tissue Doppler s prime, dP/dt, afterload dependence, hyperdynamic ventricle, longitudinal function | Cardiovascular | New / Revised 2026 | |||
load dependence, valve severity grading, vena contracta, PISA, EROA, colour jet area, acute versus chronic regurgitation, low flow state, multivalve disease, ESC EACTS 2025 | Cardiovascular | New / Revised 2026 | |||
diastolic function, ASE 2025 algorithm, E/e prime, e prime, TR velocity, LAVi, LA reservoir strain, pulmonary vein S/D, IVRT, filling pressure, exclusions, atrial fibrillation, constriction, annulus reversus | Cardiovascular | New / Revised 2026 | |||
prosthetic valve, ASE 2024, Doppler velocity index, DVI, acceleration time, effective orifice area, patient-prosthesis mismatch, structural valve deterioration, thrombus versus pannus, CT attenuation 145 HU, washing jets, paravalvular leak, acoustic shadowing | Cardiovascular | New / Revised 2026 | |||
aortic dissection, type A, intramural haematoma, penetrating atherosclerotic ulcer, TEE blind spot, true vs false lumen, dissection flap vs artefact, aortic measurement convention, leading edge, inner edge, IABP position | Vascular | New / Revised 2026 | |||
fluid responsiveness, fluid tolerance, passive leg raise, PLR, end-expiratory occlusion, mini fluid challenge, delta Vpeak, IVC distensibility, IVC collapsibility, SVC collapsibility, heart-lung interaction, tidal volume 8 mL/kg | Cardiovascular | New / Revised 2026 | |||
artefact, reverberation, side lobe, mirror image, acoustic shadowing, near-field clutter, coumadin ridge, epicardial fat pad, pericardial vs pleural effusion, descending aorta landmark, ultrasound enhancing agent, contrast echo, poor windows | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
left atrial volume index, LAVi, LA reservoir strain, LA appendage thrombus, spontaneous echo contrast, interatrial septum, PFO, patent foramen ovale, ASD, agitated saline, bubble study, Qp/Qs, post-infarction VSD, platypnoea orthodeoxia | Cardiovascular | New / Revised 2026 | |||
Doppler equation, cosine theta, insonation angle, simplified Bernoulli, expanded Bernoulli, Nyquist limit, aliasing, pulsed wave, continuous wave, tissue Doppler, VTI, velocity time integral, sweep speed | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
tamponade, pericardial effusion, RA systolic collapse, RV diastolic collapse, respiratory inflow variation, pulsus paradoxus, low-pressure tamponade, constrictive pericarditis, septal bounce, annulus reversus, pericardiocentesis | Cardiovascular | New / Revised 2026 | |||
right ventricle, TAPSE, TAPSE/PASP, RV-PA coupling, fractional area change, RV free wall strain, PASP, RVOT acceleration time, 60/60 sign, acute cor pulmonale, septal flattening, D-shaped LV, RV spiral of death | Cardiovascular | New / Revised 2026 | |||
ventriculo-arterial coupling, Ea, Ees, elastance, decoupling, end-systolic pressure volume relationship, Chen single beat, vasoplegia, unmasking, afterload mismatch | Cardiovascular | New / Revised 2026 | |||
VExUS, venous congestion, hepatic vein Doppler, portal vein pulsatility, intrarenal venous Doppler, IVC plethora, congestive nephropathy, de-resuscitation, decongestion, tricuspid regurgitation confounder | Renal | New / Revised 2026 | |||
mitral stenosis, mitral valve area, planimetry, pressure half time, 220/PHT, rheumatic, hockey stick, mitral annular calcification, Wilkins score, balloon valvuloplasty, rate control, tachycardia | Cardiovascular | New / Revised 2026 | |||
tricuspid regurgitation, massive, torrential, hepatic vein systolic reversal, lead-related TR, atrial functional TR, TRI-SCORE, transcatheter tricuspid intervention, pulmonic regurgitation, pulmonic stenosis, carcinoid | Cardiovascular | New / Revised 2026 | |||
infective endocarditis, Duke-ISCVID 2023, vegetation, perivalvular abscess, pseudoaneurysm, fistula, prosthetic valve endocarditis, TEE sensitivity, repeat imaging 5-7 days, surgical indications, vegetation size, PET/CT | Infectious Diseases | New / Revised 2026 | |||
ultrasound physics, knobology, axial and lateral resolution, attenuation, acoustic impedance, frame rate, harmonics, gain, time gain compensation, mechanical index, thermal index, ALARA, LVOT diameter error | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
NUTRIREA-1: no GRV monitoring non-inferior for VAP; ESICM AGI grading I-IV; cirrhosis-specific prokinetic survival benefit | GI & Hepatology | New / Revised 2026 | |||
PRESENCE trial: offering choice reduced PTSD; Cochrane review found insufficient evidence - genuine strong-trial-vs-cautious-meta-analysis tension | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
FEAST trial: fluid boluses increased mortality in African children, overturning global assumption | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
TADA avoids the word 'futility' deliberately; real data shows only 27 actual withdrawals from 974 consultations | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
Telestroke transforms rural hospital capability; reimbursement flows to remote specialist not local hospital - real sustainability barrier | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
Earplugs/eye masks improve sleep quality but not proven to reduce delirium; multicomponent bundles clearly superior | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
Life-threatening injury takes precedence over decontamination; 36-48h surgical window before cytopenia worsens | Environmental | New / Revised 2026 | |||
Counterintuitive chest compression finding; REBOA vs thoracotomy comparable outcomes; 77% distal thrombus rate | Trauma | New / Revised 2026 | |||
NPWT+dynamic fascial traction: 80-90% closure rates, lower mortality vs alternatives | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
Association vs causation gap; RADAR-2 subgroup harm signal in ventilated septic patients with early de-resuscitation | Renal | New / Revised 2026 | |||
Mechanism-dependent agent selection; MBL producers remain the persistent gap; colistin's genuine demotion (RESTORE-IMI 1) | Infectious Diseases | New / Revised 2026 | |||
2024 ATS guideline against routine empiric antifungals; Candida score trigger; rezafungin once-weekly dosing | Infectious Diseases | New / Revised 2026 | |||
Strong process-outcome evidence, honestly mixed hard-outcome data (HAP/VAP meta-analysis found no mortality benefit) | Infectious Diseases | New / Revised 2026 | |||
Unresolved debate: is NCSE independently harmful or just a severity marker; ictal-interictal continuum | Neurology | New / Revised 2026 | |||
2023 unified guideline: single exam sufficient; strict determination/donation conflict-of-interest separation | Neurology | New / Revised 2026 | |||
Never abruptly stop home PDE5i or iNO - rebound RV failure/pulmonary hypertension; PDE5i+nitrate contraindication | Cardiovascular | New / Revised 2026 | |||
RV systolic+diastolic coronary perfusion; norepinephrine's mixed human RV effect; caution with inodilators in RV MI | Cardiovascular | New / Revised 2026 | |||
DanGer Shock: first MCS mortality benefit ever shown (45.8% vs 58.5%); VA-ECMO downgraded to Class 3 | Cardiovascular | New / Revised 2026 | |||
Nearly half die within 1 year; half of survivors ADL-dependent at 2 years; genuine prognostic uncertainty at trach decision point | Respiratory | New / Revised 2026 | |||
REST trial found harm signal for routine use; targeted selective use per 2022 consensus may differ | Respiratory | New / Revised 2026 | |||
SUPPORT trial harm signal; conflicting modern meta-analyses; confounding by indication | Respiratory | New / Revised 2026 | |||
NPWT works for treatment (reduces mortality/reinfection) but prophylactic use showed MORE infections in one study | Cardiovascular | New / Revised 2026 | |||
Remote-HIT heparin re-exposure strategy; bivalirudin CHOOSE-ON trial; diagnostic confounding in post-CPB thrombocytopenia | Cardiovascular | New / Revised 2026 | |||
VHA-guided transfusion genuine evidence; three protamine reaction types; NPH insulin risk factor | Cardiovascular | New / Revised 2026 | |||
Flutter/VT/AV block management; low threshold for permanent pacing given late AV block risk | Cardiovascular | New / Revised 2026 | |||
Type 5 MI threshold officially 'arbitrary'; normal-troponin CABG patients hit 270x URL with no infarction | Cardiovascular | New / Revised 2026 | |||
STS Expert Consensus: 3-shock rule, 5-min resternotomy target, deliberate departure from ACLS | Cardiovascular | New / Revised 2026 | |||
PCCS-specific outcomes worse than general CS (34% vs 20-65%); combo IABP+ECMO improves weaning | Cardiovascular | New / Revised 2026 | |||
Methylene blue vs hydroxocobalamin mixed evidence; serotonin syndrome risk with methylene blue | Cardiovascular | New / Revised 2026 | |||
10-45% complex separation rate; difficulty independently predicts survival; TEE-guided approach | Cardiovascular | New / Revised 2026 | |||
Complement/coagulation activation data; multi-hit hypothesis; honest skepticism on anti-inflammatory interventions | Cardiovascular | New / Revised 2026 | |||
Jamieson classification; PA catheter balloon must NEVER be wedged post-PEA; massive hemoptysis emergency | Cardiovascular | New / Revised 2026 | |||
ISHLT PGD 0-3 grading rule; Grade 3 linked to long-term CLAD risk | Cardiovascular | New / Revised 2026 | |||
PGD drops 1-year survival 95%->75%; dd-cfDNA/GEP modern surveillance vs biopsy-only | Cardiovascular | New / Revised 2026 | |||
Conflicting DAPT trials (CASCADE/DACAB/TOP-CABG); tamponade case with wrong vasopressor choice | Cardiovascular | New / Revised 2026 | |||
DHCA vs ACP unresolved after a decade; devastating missed-malperfusion case study | Cardiovascular | New / Revised 2026 | |||
RE-ALIGN DOAC contraindication; Merie registry challenges bioprosthetic low-risk guidance; dramatic case study | Cardiovascular | New / Revised 2026 | |||
Three-tier CSC framework; Truog critique of ventilator allocation protocol workability | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
Up to 80% physician burnout; direct link to medical errors; systems approach vs individual resilience framing | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
Kirkpatrick levels 1-2 vs 3-4 gap; CVC mastery learning cut CLABSI 74% - the genuine exception | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
BIV vs LCV values framework; PARTNER trial mixed result; Schneiderman ethics consultation trial | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
28% autopsy misdiagnosis rate; bias training doesn't reliably fix real-time reasoning | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
Closed vs open ICU mortality data; tele-ICU outcome trial; nurse ratio evidence | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
Epic Sepsis Model deployment failure (AUC 0.63) vs TREWS/Sepsis Watch validated success | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
15 Gaba/Rall principles; closed-loop communication; strong sim evidence, thinner real-outcome data | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
SPIKES framework; ICUconnect trial found unequal benefit across racial groups | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
PALACS: pericardiotomy nearly halves POAF but no 30-day outcome benefit yet shown | Cardiovascular | New / Revised 2026 | |||
Miscellaneous / Cross-Cutting | Core Protocol | ||||
Miscellaneous / Cross-Cutting | Core Protocol | ||||
Miscellaneous / Cross-Cutting | Core Protocol | ||||
Miscellaneous / Cross-Cutting | Core Protocol | ||||
CONSCIOUS trials: angiographic vasospasm reduced, functional outcome not improved | Neurology | New / Revised 2026 | |||
EPaNIC, PermiT, EFFORT Protein/PRECISe/TARGET Protein | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
NOTE: overlaps with 9. Refeeding Syndrome (Endocrine) - manual review needed. Doig RCT evidence review | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
SMART vs BaSICS/PLUS; pre-enrollment fluid exposure | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
Contrast with Goals of Care's cautionary findings | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
eCASH; SPICE III/MENDS2 vs PADIS guideline tension | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
23%/30% error reduction vs weaker replication at higher study rigor | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
Prevention-during-ICU vs disappointing post-discharge evidence | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
TEAM trial's prediction-accuracy lesson | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
Carson et al. and condolence-letter harm signals | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
SAFE's rare decisive result; persistent shock-specific signal | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
CIWA-Ar's non-verbal-patient limitation; phenobarbital evidence | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
Delphi consensus; nighttime discharge mortality signal | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
PREVENT trial; LMWH vs UFH | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
PENT screening tool for non-cooperative patients | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
VIP1/VIP2/COVIP; frailty over chronological age | Miscellaneous / Cross-Cutting | New / Revised 2026 | |||
Vascular | Core Protocol | ||||
Undifferentiated ICU Syndromes | Core Protocol | ||||
Undifferentiated ICU Syndromes | Core Protocol | ||||
Undifferentiated ICU Syndromes | Core Protocol | ||||
Autoimmune & Rheumatology | Core Protocol | ||||
Autoimmune & Rheumatology | Core Protocol | ||||
Vascular | Core Protocol | ||||
Environmental | Core Protocol | ||||
Environmental | Core Protocol | ||||
Undifferentiated ICU Syndromes | Core Protocol | ||||
NOTE: possible duplicate with another 2. Ruptured AAA page - worth a manual check | Vascular | Core Protocol | |||
Undifferentiated ICU Syndromes | Core Protocol | ||||
Environmental | Core Protocol | ||||
Autoimmune & Rheumatology | Core Protocol | ||||
Autoimmune & Rheumatology | Core Protocol | ||||
Environmental | Core Protocol | ||||
Undifferentiated ICU Syndromes | Core Protocol | ||||
Toxicology | Core Protocol | ||||
Toxicology | Core Protocol | ||||
Trauma | Core Protocol | ||||
Obstetrics | Core Protocol | ||||
Obstetrics | Core Protocol | ||||
Toxicology | Core Protocol | ||||
Trauma | Core Protocol | ||||
Obstetrics | Core Protocol | ||||
Toxicology | Core Protocol | ||||
Obstetrics | Core Protocol | ||||
Obstetrics | Core Protocol | ||||
Trauma | Core Protocol | ||||
Toxicology | Core Protocol | ||||
2025 exploratory analysis narrows window to ~90 min | Trauma | New / Revised 2026 | |||
Trauma | Core Protocol | ||||
NNT 274; WOMAN-2 negative prevention result | Obstetrics | New / Revised 2026 | |||
Toxicology | Core Protocol | ||||
Trauma | Core Protocol | ||||
Trauma | Core Protocol | ||||
Trauma | Core Protocol | ||||
Obstetrics | Core Protocol | ||||
Trauma | Core Protocol | ||||
Toxicology | Core Protocol | ||||
Toxicology | Core Protocol | ||||
Hematology | Core Protocol | ||||
Hematology | Core Protocol | ||||
Full revision incorporating recent landmark trials | Hematology | New / Revised 2026 | |||
Hematology | Core Protocol | ||||
Hematology | Core Protocol | ||||
ANNEXA-I: surrogate efficacy met, clinical outcome not improved | Hematology | New / Revised 2026 | |||
Hematology | Core Protocol | ||||
Hematology | Core Protocol | ||||
Hematology | Core Protocol | ||||
HEMOTION/TRAIN exception for acute brain injury | Hematology | New / Revised 2026 | |||
2022 SHEA/IDSA updates; SDD flagged as unresolved | Infectious Diseases | New / Revised 2026 | |||
Infectious Diseases | Core Protocol | ||||
SIRS/MEWS over qSOFA; source control timing; active de-resuscitation | Infectious Diseases | New / Revised 2026 | |||
Infectious Diseases | Core Protocol | ||||
Pooled-vs-individual-trial tension | Infectious Diseases | New / Revised 2026 | |||
Infectious Diseases | Core Protocol | ||||
BALANCE trial; source-control-dependent duration table | Infectious Diseases | New / Revised 2026 | |||
Contrasts with TTM's fever-avoidance recommendation | Infectious Diseases | New / Revised 2026 | |||
Augmented renal clearance; BLING III Bayesian reframing | Infectious Diseases | New / Revised 2026 | |||
Single-center enthusiasm to LOVIT harm signal | Infectious Diseases | New / Revised 2026 | |||
Infectious Diseases | Core Protocol | ||||
Infectious Diseases | Core Protocol | ||||
Full revision incorporating March 2026 SSC guideline | Infectious Diseases | New / Revised 2026 | |||
ADRENAL vs APROCCHSS discordance; fludrocortisone practice gap | Infectious Diseases | New / Revised 2026 | |||
Shrinking effect size as fixed-duration stewardship matures | Infectious Diseases | New / Revised 2026 | |||
Endocrine & Metabolic | Core Protocol | ||||
Endocrine & Metabolic | Core Protocol | ||||
Endocrine & Metabolic | Core Protocol | ||||
Endocrine & Metabolic | Core Protocol | ||||
Endocrine & Metabolic | Core Protocol | ||||
Endocrine & Metabolic | Core Protocol | ||||
Leuven-to-NICE-SUGAR arc; 140-180 mg/dL standard | Endocrine & Metabolic | New / Revised 2026 | |||
Endocrine & Metabolic | Core Protocol | ||||
Endocrine & Metabolic | Core Protocol | ||||
NOTE: overlapping deep-dive exists in Miscellaneous Topics - see index note | Endocrine & Metabolic | Core Protocol | |||
Renal | Core Protocol | ||||
Renal | Core Protocol | ||||
Renal | Core Protocol | ||||
Renal | Core Protocol | ||||
Renal | Core Protocol | ||||
Propensity-matched/counterfactual evidence vs traditional teaching | Renal | New / Revised 2026 | |||
Renal | Core Protocol | ||||
STARRT-AKI; watchful-waiting with defined boundary | Renal | New / Revised 2026 | |||
Renal | Core Protocol | ||||
GI & Hepatology | Core Protocol | ||||
GI & Hepatology | Core Protocol | ||||
GI & Hepatology | Core Protocol | ||||
GI & Hepatology | Core Protocol | ||||
GI & Hepatology | Core Protocol | ||||
GI & Hepatology | Core Protocol | ||||
GI & Hepatology | Core Protocol | ||||
GI & Hepatology | Core Protocol | ||||
GI & Hepatology | Core Protocol | ||||
GI & Hepatology | Core Protocol | ||||
Practice-resolving REVISE trial | GI & Hepatology | New / Revised 2026 | |||
GI & Hepatology | Core Protocol | ||||
GI & Hepatology | Core Protocol | ||||
GI & Hepatology | Core Protocol | ||||
ABCDEF bundle; MIND-USA, AID-ICU, melatonin controversy | Neurology | New / Revised 2026 | |||
Neurology | Core Protocol | ||||
Neurology | Core Protocol | ||||
Neurology | Core Protocol | ||||
Neurology | Core Protocol | ||||
Neurology | Core Protocol | ||||
Neurology | Core Protocol | ||||
Neurology | Core Protocol | ||||
Neurology | Core Protocol | ||||
Neurology | Core Protocol | ||||
Neurology | Core Protocol | ||||
Neurology | Core Protocol | ||||
Neurology | Core Protocol | ||||
Phenotype-driven agent selection; SSC ladder | Cardiovascular | New / Revised 2026 | |||
Cardiovascular | Core Protocol | ||||
TTM2; fever prevention vs hypothermia; HYPERION exception | Cardiovascular | New / Revised 2026 | |||
EF-mortality dissociation; RV dysfunction as better marker | Cardiovascular | New / Revised 2026 | |||
Cardiovascular | Core Protocol | ||||
Cardiovascular | Core Protocol | ||||
Cardiovascular | Core Protocol | ||||
ARREST vs INCEPTION; systems-dependency of outcomes | Cardiovascular | New / Revised 2026 | |||
Cardiovascular | Core Protocol | ||||
Catheter-directed thrombolysis intermediate-high-risk PE | Cardiovascular | New / Revised 2026 | |||
Cardiovascular | Core Protocol | ||||
Cardiovascular | Core Protocol | ||||
Cardiovascular | Core Protocol | ||||
Morelli's dramatic result vs STRESS-L's harm signal | Cardiovascular | New / Revised 2026 | |||
Cardiovascular | Core Protocol | ||||
Dynamic vs static measures; CLASSIC/CLOVERS equipoise | Cardiovascular | New / Revised 2026 | |||
Cardiovascular | Core Protocol | ||||
Cardiovascular | Core Protocol | ||||
Frequentist negative vs 96% Bayesian posterior probability | Respiratory | New / Revised 2026 | |||
Respiratory | Core Protocol | ||||
Clinical-prediction-failure lesson | Respiratory | New / Revised 2026 | |||
Respiratory | Core Protocol | ||||
Respiratory | Core Protocol | ||||
Dose-response explanation for largest single-trial effect | Respiratory | New / Revised 2026 | |||
Risk-stratified extubation planning; NIV/HFNC timing | Respiratory | New / Revised 2026 | |||
Respiratory | Core Protocol | ||||
Respiratory | Core Protocol | ||||
UK-ROX 2025; population-specific signals | Respiratory | New / Revised 2026 | |||
Respiratory | Core Protocol | ||||
MACOCHA, DAS 2025, SOCCA Delphi, INTUBE | Respiratory | New / Revised 2026 | |||
Primary-vs-secondary-outcome caution; HIGH trial discordance | Respiratory | New / Revised 2026 | |||
Comparator drift, not the drug, explains the discordance | Respiratory | New / Revised 2026 | |||
Respiratory | Core Protocol | ||||
Respiratory | Core Protocol | ||||
Ehrmann meta-trial; dose-response duration finding | Respiratory | New / Revised 2026 | |||
Respiratory | Core Protocol | ||||
Respiratory | Core Protocol | ||||
Respiratory | Core Protocol | ||||
Subira's mortality finding and co-intervention confound | Respiratory | New / Revised 2026 | |||
Respiratory | Core Protocol | ||||
Agent-specific divergence under shared negative headline | Respiratory | New / Revised 2026 | |||
Respiratory | Core Protocol |